Skip to main content

Market Overview

Lannet Company Announces FDA Approval Of Nasal Spray, Shares Tick Higher


Shares of Lannet Company, Inc. (NYSE: LCI) were trading higher by more than 1 percent on Monday after the company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its nasal spray.

Lannet Company noted that the FDA granted an Abbreviated New Drug Application (ANDA) for its nasal spray, Sumatriptan. The company added that its product is the therapeutic equivalent to GlaxoSmithKline plc (ADR) (NYSE: GSK)'s Imitrex nasal spray.

"We believe our Sumatriptan Nasal Spray USP, 5 mg/spray and 20 mg/spray will be a first-to-market generic product," said Arthur Bedrosian, chief executive officer of Lannett.

"Producing nasal delivery medications requires unique expertise and facilities that few possess. Our Sumatriptan Nasal Spray product was developed by Summit Biosciences Inc. and will be manufactured at its state-of-the-art facility located on the University of Kentucky's Coldstream Research Campus. We expect to commence marketing the product in the next several months."


Related Articles (LCI + GSK)

View Comments and Join the Discussion!

Posted-In: ANDA Imitrex Lannet Company Nasal Spray SumatriptanNews FDA Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at